Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018